Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology
+$0.09 today
- Market cap
- $595.91M
- Beta
- 0.10
- P/E (TTM)
- -10.1
- EPS (TTM)
- -$0.91
Volume 0.88M
Average 1.07M
IMMX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Immix Biopharma, Inc.NASDAQ: IMMX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns negative
Q1 FY2026 financing cash flow was -$37.56K, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $107.35M. Over 3 fiscal years it compounded at +221.5% a year.
Context
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near -$37.56K or moves back toward the trailing-twelve-month quarterly average of $26.84M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 107.39M USD
- Year-over-year change
- +573.3%
- 4-year CAGR
- +54.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 107.39M | +573.3% |
| FY2024 | 2024-12-31 | 15.95M | +3.1% |
| FY2023 | 2023-12-31 | 15.46M | +378.4% |
| FY2022 | 2022-12-31 | 3.23M | -82.9% |
| FY2021 | 2021-12-31 | 18.85M | — |
Financing Cash Flow vs competitors
How IMMX compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Over three fiscal years its annual growth of +221.5% compares with a peer median of +145.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €531.94M EUR | +1785.8% | +154.7% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥433.38M CNY | — | +10.9% | — |
| LTM Mar 2026 | $344.93M USD | +4594.2% | +454.4% | 970.5% | |
| LTM Sep 2026 | $327.45M USD | +22878.8% | -16.3% | 292364.3% | |
| LTM Jun 2026 | $313M USD | +30.4% | +145.5% | 267.5% | |
| LTM Aug 2026 | $261.21M USD | +28.6% | +26.8% | 37.2% | |
| LTM Mar 2026 | $254.22M USD | +330054.5% | -11.9% | — | |
| LTM Mar 2026 | $107.35M USD | — | +221.5% | — | |
| LTM Mar 2026 | $69.59M USD | +16083.5% | +247.3% | 44.3% | |
| LTM Mar 2026 | $2.68M USD | -95.0% | +225.3% | 511.0% | |
| FY2025 | A$525.12K AUD | -100.6% | — | 10.4% | |
| Peer median (excluding IMMX) | — | +1785.8% | +145.5% | 267.5% | |
Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.38M) | (8.23M) | (15.6M) | (21.61M) | (29.44M) |
| Depreciation & Amortization | 2.47K | 2.14K | 5.47K | 115.39K | 364.5K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 218.98K | 624.07K | 2.57M | 3.02M | 2.44M |
| Change in Working Capital | (391.04K) | 195.21K | 1.65M | 3.97M | 2.7M |
| Accounts Receivables | 97.67K | (236.38K) | (893.4K) | (971.53K) | 2.06M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (106.06K) | 1.13M | 2.43M | 4.4M | 1.03M |
| Other Working Capital | (382.64K) | (700.15K) | 111.84K | 537.2K | (384.74K) |
| Other Non-Cash Items | 22.96M | 0 | 0 | 2.94M | 0 |
| Operating Cash Flow | (1.59M) | (7.41M) | (11.37M) | (14.6M) | (23.93M) |
| Capital Expenditures | (802) | 3 | (52.09K) | (1.18M) | (732.93K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (6.48M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (802) | 0 | (52.09K) | (1.18M) | (7.21M) |
| Debt Repayment | 200K | (50K) | 0 | 0 | 0 |
| Common Stock Issued | 18.65M | 3.39M | 15.7M | 15.95M | 107.39M |
| Common Stock Repurchased | 0 | (99.96K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (6.72K) | (232K) | 0 | 0 |
| Financing Cash Flow | 18.85M | 3.23M | 15.46M | 15.95M | 107.39M |
| Effect of Forex Changes | (5.43K) | (31.52K) | 33.09K | (3.62K) | 3.84K |
| Net Change in Cash | 17.25M | (4.21M) | 4.07M | 172.16K | 76.25M |
| Free Cash Flow | (1.59M) | (7.41M) | (11.42M) | (15.77M) | (24.66M) |
Immix Biopharma, Inc.
NASDAQ:IMMX
Intrinsic Alpha fair value
Locked
Current Price
$7.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.